ALGS
insider transactionsAligos Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
Transactions · 365d
-
Grant·A
See Remarks
$0
23.3K sh
Own New
-
Grant·A
See Remarks
$0
37.5K sh
Own New
-
Grant·A
BLATT LAWRENCE KEY
President and CEO
$0
105.8K sh
Own New
-
Grant·A
Principal Accounting Officer
$0
9.4K sh
Own New
-
Grant·A
BLATT LAWRENCE KEY
President and CEO
$0
179.8K sh
Own New
-
Grant·A
See Remarks
$0
16.0K sh
Own New
-
Grant·A
See Remarks
$0
40.2K sh
Own New
-
Grant·A
Director
$0
5.9K sh
Own New
-
Grant·A
Director
$0
5.9K sh
Own New
-
Grant·A
Director
$0
5.9K sh
Own New
-
Grant·A
Director
$0
5.9K sh
Own New
-
Grant·A
Director
$0
5.9K sh
Own New
-
Grant·A
Director
$0
5.9K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 9, 2026 | Symons Julian A. | Grant A | 23.3K | $0 |
| Mar 9, 2026 | Calhoun Lesley Ann | Grant A | 37.5K | $0 |
| Mar 9, 2026 | BLATT LAWRENCE KEY | Grant A | 105.8K | $0 |
| Mar 9, 2026 | Aneja Nikhil | Grant A | 9.4K | $0 |
| Jul 16, 2025 | BLATT LAWRENCE KEY | Grant A | 179.8K | $0 |
| Jul 16, 2025 | Symons Julian A. | Grant A | 16.0K | $0 |
| Jul 16, 2025 | Calhoun Lesley Ann | Grant A | 40.2K | $0 |
| Jun 25, 2025 | Martell Bridget A | Grant A | 5.9K | $0 |
| Jun 25, 2025 | Nuechterlein Carole | Grant A | 5.9K | $0 |
| Jun 25, 2025 | Hirth Peter | Grant A | 5.9K | $0 |
| Jun 25, 2025 | Chavez Margarita | Grant A | 5.9K | $0 |
| Jun 25, 2025 | Preston Heather | Grant A | 5.9K | $0 |
| Jun 25, 2025 | Scopa James Paul | Grant A | 5.9K | $0 |
Buy Sell Non-market (grant · exercise · gift)
About ALGS insider trading
This page tracks insider transactions for Aligos Therapeutics, Inc. (ALGS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.